Rivaroxaban (modification-I) contains not less than 98.5% and not more than 101.5% of C19H18ClN3O5S, calculated on the anhydrous basis.

利伐沙班
Rivaroxaban

申請商
鴻傑藥品有限公司 
適應症
抗凝血劑
含量
0